Effectiveness and safety of the Trevo (R) Retriever for mechanical thrombectomy in Chinese patients with acute ischemic stroke: Trevo Retriever China Registry

Background To quantify the effectiveness and safety of the Trevo (R) Retriever for endovascular treatment of acute ischemic stroke (AIS) patients in China. Methods Trevo Retriever Registry (China) was a prospective, multicenter, non-comparative, open-label study of patients with AIS treated with the Trevo Retriever. The primary outcome was the proportion of patients achieving an expanded Thrombolysis in Cerebral Infarction (eTICI) score >= 2b at the end of endovascular treatment. Secondary outcomes included first-pass eTICI score >= 2b and 90-day modified Rankin Scale (mRS) score <= 2. Results The Trevo Retriever Registry (China) enrolled and followed 201 patients (62.1 +/- 12.5 years-old; 70.6% male) at 11 centers. The pre-procedure NIHSS score and ASPECTS were 16 (interquartile range (IQR), 13-21) and 7 (IQR, 6-9), respectively, and 188 (93.5%) patients had an mRS score of 0 prior to the stroke. The main stroke etiology was large artery atherosclerosis, accounting for 71.6% (144/201) of patients. Post-procedure eTICI >= 2b was 98.4% (187/190). First-pass eTICI >= 2b was 74.7% (136/182). The 90-day good outcome (mRS <= 2) rate was 73.6% (148/201). The 90-day all-cause mortality was 5.5% (11/201). Neurological deterioration at 24 h post-procedure was observed in 7.7% (15/195) patients. Embolism in a new territory was seen in one patient (0.5%). Two (1.0%) procedure-related adverse events (AEs) occurred, which were intra-procedure cerebral artery embolism. No Trevo related AEs occurred. Conclusions This real-world study of the Trevo Retriever in China demonstrated a high rate of revascularization and first-pass success that resulted in an overall high good function outcome rate and low mortality.